ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1043

Prevalence of Multimorbidity in Cutaneous Lupus Erythematosus: A Population-Based Study

Mehmet Hocaoglu1, Mark Davis2, Maria Valenzuela-Almada3, Jesse Dabit2, Shirley-Ann Osei-Onomah2, Sebastian Vallejo-Ramos2, Tina Gunderson2, Kurt Greenlund4, Kamil Barbour4, Cynthia Crowson5 and Ali Duarte-Garcia2, 1University of Maryland Medical Center, Midtown Campus, Baltimore, MD, 2Mayo Clinic, Rochester, MN, 3Division of Rheumatology, Mayo Clinic, Rochester, MN, 4Centers for Disease Control, Atlanta, GA, 5Mayo Clinic, Eyota, MN

Meeting: ACR Convergence 2021

Keywords:

Session Information

Date: Monday, November 8, 2021

Title: Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Cutaneous lupus erythematosus (CLE) patients report impaired quality of life due to cutaneous and psychological morbidity. Previous literature on the prevalence of comorbidities in CLE patients is scarce and the extent of multimorbidity is uncertain. In this population-based study, we aimed to characterize the prevalence of multimorbidity in CLE patients.

Methods: Prevalent CLE cases from a well-defined 27-county region in the United States were included in our study. Cases with concomitant systemic lupus erythematosus (SLE) meeting ACR/EULAR 2019 criteria were excluded. Subjects identified as CLE were age-, sex-, race-, and county-matched to non-CLE subjects from the same population. A five-year lookback period was used for diagnostic codes to determine the presence of comorbidities. Two or more codes ≥30 days apart were used to define a comorbidity. A previously published list of 44 comorbidities was considered (England et al. ARD 2020). CLE and SLE codes were excluded from the analysis. Two or more comorbidities were defined as multimorbidity, 5 or more as substantial multimorbidity. Logistic regression models adjusted for age and sex were used.

Results: 303 CLE patients were matched to 303 non-CLE controls from the same population. The mean age was 59.4 (SD 15.7) years. 72.9% were female. 90.8% were White. CLE patients had 4.7 comorbidities on average compared to 4.0 of non-CLE subjects. Multimorbidity was present in 79.5% CLE vs. 65.7% non-CLE (OR:2.27; 95CI:1.53-3.38) and substantial multimorbidity was present in 43.9% CLE patients vs. 34.3% non-CLE subjects (OR:1.65; 95CI:1.14-2.38). Fibromyalgia, liver disease, chronic obstructive pulmonary disease (COPD), hypertension, anemia, and hypothyroidism were significantly more common in CLE patients compared to controls (Table).

Conclusion: In this population-based study, CLE patients were 2 times more likely to have multimorbidity compared to the general population. It is unclear if the driver of multimorbidity in CLE is the disease itself, treatments, or a combination thereof.

Disclosures: M. Hocaoglu, None; M. Davis, None; M. Valenzuela-Almada, None; J. Dabit, None; S. Osei-Onomah, None; S. Vallejo-Ramos, None; T. Gunderson, None; K. Greenlund, None; K. Barbour, None; C. Crowson, None; A. Duarte-Garcia, None.

To cite this abstract in AMA style:

Hocaoglu M, Davis M, Valenzuela-Almada M, Dabit J, Osei-Onomah S, Vallejo-Ramos S, Gunderson T, Greenlund K, Barbour K, Crowson C, Duarte-Garcia A. Prevalence of Multimorbidity in Cutaneous Lupus Erythematosus: A Population-Based Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-multimorbidity-in-cutaneous-lupus-erythematosus-a-population-based-study/. Accessed .

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-multimorbidity-in-cutaneous-lupus-erythematosus-a-population-based-study/